Head to head
LillyDirect vs OrderlyMeds: Pricing, Evidence and What Neither Discloses
We hold captured pricing for LillyDirect only, so a like-for-like price comparison is not possible yet.
On their own pages, read November 20, 2026 or later, OrderlyMeds lists $299 month to month and $149 at its lowest (2 months for $299 for new customers, then $299 a month); LillyDirect could not be read on November 20–21, 2026, so there is no like-for-like tirzepatide price comparison. On our written v4.1 scoring guide, LillyDirect is not scored and OrderlyMeds scores 56/100 (#16 of 22).
The short answer
We hold captured pricing for LillyDirect only, so a like-for-like price comparison is not possible yet. Both figures are provider-reported.
Price is one of five fields that matter, and it is the only one either company reliably publishes. The others — which pharmacy fills the prescription, whether the price holds as your dose rises, what is refunded if you stop, and whether the programme can lawfully serve your state — are unverified for both.
Compare at a maintenance dose, not at signup
The tirzepatide label describes 2.5 mg as treatment initiation and states it is not approved as a maintenance dosage. You take it for four weeks and then never again. Where a programme tiers by dose, the advertised figure is usually that starting dose — so a comparison built on it ranks these two on a price neither charges after month one.
Ask both for the all-in monthly cost at 10 mg, which is a recommended maintenance dosage, and compare those.
What neither has told us
Neither LillyDirect nor OrderlyMeds has named its fulfilling pharmacy or its registration class. That is true of most providers in our dataset (NexLife’s plan pages do name three 503A pharmacies), and it is the question we would put first if you can only ask one — because the FDA has proposed excluding tirzepatide from the 503B bulks list, and whether your supply runs through a 503B outsourcing facility or a 503A pharmacy determines your exposure to that decision.
The comparison that outranks both
Check insurance first. Where a commercial plan covers Zepbound or Wegovy the cost can be near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both sit below every self-pay route including every compounded programme in our dataset.
Failing that, brand Zepbound is $299 to $449 direct from LillyDirect and both approved oral GLP-1s start at $149 — figures worth having in front of you before choosing between two compounded programmes.
Show this figure as a table
| Item | LillyDirect | OrderlyMeds |
|---|---|---|
| Tirzepatide | $299 | not captured |
| Semaglutide | not captured | not captured |
| Field | LillyDirect | OrderlyMeds |
|---|---|---|
| Lowest captured all-in | $149/mo | not verified |
| Lowest tirzepatide | $299/mo | not verified |
| Lowest semaglutide | not verified | not verified |
| Records we hold | 2 | 0 |
| Evidence status | Provider-reported Provider-reported | Provider-reported Provider-reported |
| Fulfilling pharmacy named to us | no | no |
| Registration class disclosed | no | no |
| State availability verified | no | no |
| Cancellation terms captured | not verified | not verified |
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| LillyDirect | manufacturer_direct | brand oral, FDA-approved | not recorded | $149 | not verified | $149 | Recurring | Provider-reported | 2026-07-06 |
| LillyDirect | manufacturer_direct | brand injectable, FDA-approved | not recorded | $299 | not verified | $299 | Recurring | Provider-reported | 2026-07-06 |
Our editorial pick, NexLife, charges $129 a month for compounded tirzepatide month to month, or $115 a month on a 12-month plan (as of November 20, 2026), the same price at every dose with no membership fee. See NexLife’s current plans.
Questions readers actually ask
Is LillyDirect cheaper than OrderlyMeds?
On their own pages, read November 20, 2026 or later, OrderlyMeds lists $299 month to month and $149 at its lowest (2 months for $299 for new customers, then $299 a month); LillyDirect could not be read on November 20–21, 2026, so there is no like-for-like tirzepatide price comparison.
Why is one marked verified and the other reported?
On our written v4.1 scoring guide, LillyDirect is not scored and OrderlyMeds scores 56/100 (#16 of 22). The scores come from each program’s own pages and FDA’s warning-letter index, read November 20–21, 2026.
Does either name its pharmacy?
LillyDirect: not read. OrderlyMeds: ‘State-licensed pharmacies or FDA-registered outsourcing facilities, as applicable’; none named.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide Cost in 2026Pillar / Money
- Ro Body vs Mochi HealthComparisons
- Ro Body Tirzepatide ReviewProviders
Related coverage
GLP-1 Tirzepatide Review. “LillyDirect vs OrderlyMeds: Pricing, Evidence and What Neither Discloses.” S.J Partners LLC, 2026-07-26. https://glptirzepatidereview.com/compare/lillydirect-vs-orderlymeds/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.